Assignee
INTRA CELLULAR THERAPIES INC
US·137 granted patents·74 pending applications·2,452 citations·filing 2006–2025
Top patents by PatentIndex Score
211 records- 0199US11407751B2Hydrochloric acid salt of (6bR,10aS)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalineINTRA CELLULAR THERAPIES INC·Filed 2019·Granted Aug 9, 2022·19 cites·1 claims
- 0299US11331316B2Amorphous solid dispersionsINTRA CELLULAR THERAPIES INC·Filed 2017·Granted May 17, 2022·27 cites·20 claims
- 0399US10702522B2Methods and compositions for sleep disorders and other disordersINTRA CELLULAR THERAPIES INC·Filed 2018·Granted Jul 7, 2020·40 cites·12 claims
- 0499US10117867B2Methods and compositions for sleep disorders and other disordersINTRA CELLULAR THERAPIES INC·Filed 2017·Granted Nov 6, 2018·57 cites·28 claims
- 0599US9371324B2Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disordersINTRA CELLULAR THERAPIES INC·Filed 2015·Granted Jun 21, 2016·90 cites·26 claims
- 0699US9168258B2Methods and compositions for sleep disorders and other disordersINTRA CELLULAR THERAPIES INC·Filed 2013·Granted Oct 27, 2015·106 cites·20 claims
- 0798US12128043B2Pharmaceutical capsules comprising lumateperone mono-tosylateINTRA CELLULAR THERAPIES INC·Filed 2024·Granted Oct 29, 2024·10 cites·29 claims
- 0898US12090155B2MethodsINTRA CELLULAR THERAPIES INC·Filed 2023·Granted Sep 17, 2024·13 cites·27 claims
- 0998US12070459B2Pharmaceutical capsule compositions comprising lumateperone mono-tosylateINTRA CELLULAR THERAPIES INC·Filed 2023·Granted Aug 27, 2024·16 cites·28 claims
- 1098US12023331B2MethodsINTRA CELLULAR THERAPIES INC·Filed 2020·Granted Jul 2, 2024·10 cites·26 claims
- 1198US11958852B2Compounds and methodsINTRA CELLULAR THERAPIES INC·Filed 2021·Granted Apr 16, 2024·11 cites·16 claims
- 1298US11844757B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2020·Granted Dec 19, 2023·10 cites·14 claims
- 1398US11806347B2Transmucosal methods for treating psychiatric and neurological conditionsINTRA CELLULAR THERAPIES INC·Filed 2021·Granted Nov 7, 2023·20 cites·58 claims
- 1498US11806348B2Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylateINTRA CELLULAR THERAPIES INC·Filed 2022·Granted Nov 7, 2023·18 cites·23 claims
- 1598US11773095B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2022·Granted Oct 3, 2023·9 cites·21 claims
- 1698US11753419B24-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disordersINTRA CELLULAR THERAPIES INC·Filed 2020·Granted Sep 12, 2023·6 cites·26 claims
- 1798US11723909B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2021·Granted Aug 15, 2023·18 cites·34 claims
- 1898US11690842B2Pharmaceutical capsule compositions comprising lumateperone mono-tosylateINTRA CELLULAR THERAPIES INC·Filed 2021·Granted Jul 4, 2023·11 cites·20 claims
- 1998US11680065B2Pharmaceutical compositions comprising 4-(6Br,10aS)-3-methyl-2, 3, 6b, 9, 10, 10a-hexahydro-1H, 7H-pyrido[3′, 4′, 5] pyrolo[1,2,3-de] quinoxalin-8YL)-1-(4-fluorophenyl)-butane-1-one and methods of treating conditions of the central nervous systemINTRA CELLULAR THERAPIES INC·Filed 2020·Granted Jun 20, 2023·17 cites·19 claims
- 2098US11560382B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2020·Granted Jan 24, 2023·17 cites·25 claims
- 2198US11453670B2Substituted heterocycle fused gamma-carbolines synthesisINTRA CELLULAR THERAPIES INC·Filed 2019·Granted Sep 27, 2022·15 cites·28 claims
- 2298US11427587B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2018·Granted Aug 30, 2022·31 cites·13 claims
- 2398US11311536B2Amorphous solid dispersionsINTRA CELLULAR THERAPIES INC·Filed 2018·Granted Apr 26, 2022·25 cites·17 claims
- 2498US11124514B2Compositions and methodsINTRA CELLULAR THERAPIES INC·Filed 2019·Granted Sep 21, 2021·40 cites·14 claims
- 2598US11096944B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2020·Granted Aug 24, 2021·28 cites·28 claims
- 2698US11052084B2Pharmaceutical capsule compositions comprising lumateperone mono-tosylateINTRA CELLULAR THERAPIES INC·Filed 2020·Granted Jul 6, 2021·18 cites·18 claims
- 2798US11053245B2MethodsINTRA CELLULAR THERAPIES INC·Filed 2013·Granted Jul 6, 2021·40 cites·19 claims
- 2898US11052083B2Transmucosal methods for treating psychiatric and neurological conditionsINTRA CELLULAR THERAPIES INC·Filed 2020·Granted Jul 6, 2021·27 cites·26 claims
- 2998US11026951B2Methods of treating bipolar disorderINTRA CELLULAR THERAPIES INC·Filed 2019·Granted Jun 8, 2021·38 cites·24 claims
- 3098US10960010B2Pharmaceutical compositions for sustained or delayed releaseINTRA CELLULAR THERAPIES INC·Filed 2019·Granted Mar 30, 2021·38 cites·24 claims
- 3198US10960009B2Methods of treating schizophrenia and depressionINTRA CELLULAR THERAPIES INC·Filed 2019·Granted Mar 30, 2021·39 cites·19 claims
- 3298US10899762B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2020·Granted Jan 26, 2021·29 cites·21 claims
- 3398US10844061B2Pharmaceutical compositions comprising 4-(6BR,10AS)-3-methyl-2,3,6B,9,10,10A-hexahydro-1h, 7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-one and methods of treating conditions of the central nervous systemINTRA CELLULAR THERAPIES INC·Filed 2019·Granted Nov 24, 2020·33 cites·17 claims
- 3498US10799500B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2019·Granted Oct 13, 2020·28 cites·17 claims
- 3598US10688097B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2017·Granted Jun 23, 2020·48 cites·23 claims
- 3698US10597394B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2018·Granted Mar 24, 2020·30 cites·13 claims
- 3798US10472359B2Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl) butan-1-one for inhibiting serotonin reuptake transporter activityINTRA CELLULAR THERAPIES INC·Filed 2018·Granted Nov 12, 2019·35 cites·20 claims
- 3898US10464938B2Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereofINTRA CELLULAR THERAPIES INC·Filed 2019·Granted Nov 5, 2019·33 cites·12 claims
- 3998US10322134B2MethodsINTRA CELLULAR THERAPIES INC·Filed 2018·Granted Jun 18, 2019·49 cites·20 claims
- 4098US10245260B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2017·Granted Apr 2, 2019·38 cites·15 claims
- 4198US10077267B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2015·Granted Sep 18, 2018·69 cites·18 claims
- 4298US10072010B2Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activityINTRA CELLULAR THERAPIES INC·Filed 2017·Granted Sep 11, 2018·53 cites·16 claims
- 4398US9956227B2Method for the treatment of residual symptoms of schizophreniaINTRA CELLULAR THERAPIES INC·Filed 2014·Granted May 1, 2018·78 cites·25 claims
- 4498US9751883B2Preparation of certain [((6BR,10AS)-2,3,6B,7,8,9,10, 10A-octahydro-1H-pyrido[3′,4′:4,5]pyrrolo [1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereofINTRA CELLULAR THERAPIES INC·Filed 2016·Granted Sep 5, 2017·86 cites·28 claims
- 4598US9745300B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2015·Granted Aug 29, 2017·82 cites·40 claims
- 4698US9708322B2Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activityINTRA CELLULAR THERAPIES INC·Filed 2014·Granted Jul 18, 2017·93 cites·7 claims
- 4798US9616061B2Methods and compositions for sleep disorders and other disordersINTRA CELLULAR THERAPIES INC·Filed 2015·Granted Apr 11, 2017·93 cites·29 claims
- 4898US9428506B2Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disordersINTRA CELLULAR THERAPIES INC·Filed 2013·Granted Aug 30, 2016·82 cites·30 claims
- 4998US9315504B2Preparation of 4-((6BR,10AS)-3-methyl-2,3,6B,9,10, 10A-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo [1,2,3-de]quinoxalin-8-(7H)-yl)-1-(4-fluorophenyl)-1-butanone or a pharmaceutically acceptable salt thereofINTRA CELLULAR THERAPIES INC·Filed 2014·Granted Apr 19, 2016·88 cites·5 claims
- 5097US12122792B2Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disordersINTRA CELLULAR THERAPIES INC·Filed 2023·Granted Oct 22, 2024·3 cites·35 claims
Showing the top 50 of 211 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when INTRA CELLULAR THERAPIES INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →